



2020

A

55,000.00

1		31,301.88	26,500.00
2		15,000.00	12,500.00
3		16,000.00	16,000.00
		62,301.88	55,000.00

1

2

3.22

/ 21.45 /

2

3.13

1	30,101.88	26,500.00	96.17%
1.1	27,855.35	26,500.00	88.99%
1.1.1	15,266.42	14,500.00	48.77%
1.1.2	12,588.93	12,000.00	40.22%
1.2	1,446.52	-	4.62%
1.3	800.00	-	2.56%
2	1,200.00	-	3.83%
3	31,301.88	26,500.00	100%

31,301.88

26,500.00

2

1

2018

20

2

HBV

7,000

2

CHB

2,000 3,000

HCV

1,000

90%

3

3

7,000

2,000

3,000

2011

68.81

2015

WHO 2015 7,100 39.9
HCV 1,000

2012 20.16 2018 21.94
25% 20%
3% 10%

WHO 2016 2030
PR
PegIFN RBV DAAs
2017 DAAs
PR
DAAs DAAs
DAAs DAAs
90%
12 DAAs
DAAs 50%
IQVIAMIDAS 2018 DAAs 166
DAAs
2014
2017-2020 2020
HCV 100%
-HCV

2019 8 30
2020 12 31

cGMP 5 PDE5
2 cGMP

ED

ED

2015

ED

6.97%

ED

ED

80%

2014

2018

ED

28.5

60%

ED

50

ED

ED

ED

2019 7 30
2020 12 31

2

3

7,533.25

11,396.54

7,004.78

80

4

3.13 2
37,441.02 5,462.80

5

1

2

		2019 J070028
		2020 1
		2020 H020004
		2020 34

1

2.5

10 /

1 /

2.5

1.50

1	14,427.03	12,500.00	96.18%
1.1	13,273.22	12,500.00	88.49%
1.1.1	7,344.09	7,000.00	48.96%
1.1.2	5,929.13	5,500.00	39.53%
1.2	825.99	-	5.51%
1.3	327.82	-	2.19%
2	572.97	-	3.82%
3	15,000.00	12,500.00	100.00%

15,000.00

12,500.00

2

1

2030

2020

15,823

15%

29.26%

33.26%

2

3

15-64
2030 60 30%

3

1

10,000

			Lancet
2020	1	1-20	99
	43		1

2018 1.2

2018 330

2

3

2017 1,004 2018
1,234 20% 2019
1,500

4

1.50 2.5
42,345.38 3,370.07

5

1

2

	2019 260
	2019 72

1

16,000

2020

A

2020 4 1